|
Leicester to test turmeric's
cancer-fighting properties
11th May 2012
Scientists
at the Cancer Research UK and National Institute
for Health Research Experimental Cancer Medicine
Centre (ECMC) in Leicester will investigate whether
tablets containing curcumin - found in the spice
turmeric - can be safely added to the standard treatment
for bowel cancer that has spread. Earlier studies
have shown that curcumin can enhance the ability
of chemotherapy to kill bowel cancer cells in the
lab. Patients with advanced bowel cancer are usually
given a treatment called Folfox, which combines
three chemotherapy drugs. But around 40-60 per cent
of patients dont respond and, of those who
do, side effects such as severe tingling or nerve
pain can limit the number of cycles patients can
have.
Chief investigator Professor
William Steward, ECMC director at the University
of Leicester, said: Once bowel cancer has
spread it is very difficult to treat, partly because
the side effects of chemotherapy can limit how
long patients can have treatment. The prospect
that curcumin might increase the sensitivity of
cancer cells to chemotherapy is exciting because
it could mean giving lower doses, so patients
have fewer side effects and can keep having treatment
for longer.
This research is at
a very early stage, but investigating the potential
of plant chemicals to treat cancer is an intriguing
area that we hope could provide clues to developing
new drugs in the future. The trial is being
funded by Hope Against Cancer, The Royal College
of Surgeons and the Bowel Disease Research Foundation.
Leicester Experimental Cancer Medicine Centre
(ECMC) has recently been awarded £1.1 million
from Cancer Research UK and the National Institute
for Health Research (NIHR), to fund the centre
for a further five years.
Around 40 patients with bowel
cancer that has spread to the liver will be recruited
to take part in the study at Leicester Royal Infirmary
and Leicester General Hospital. Three quarters
of these will be given curcumin tablets for seven
days, before being treated with Folfox. The remainder
will receive Folfox only.
Colin Carroll, a 62-year-old
compliance consultant from near Loughborough,
agreed to take part in the trial after being diagnosed
with advanced bowel cancer in January. The
diagnosis came as a big shock because Id
had no symptoms apart from some occasional cramps,
said Colin. Id had a few tests which
had come back clear and Id just been booked
for a CT scan when I was rushed to hospital with
a suspected intestinal blockage. Scans showed
Colin had bowel cancer which had spread to his
liver and, three days after being admitted to
Leicester Royal Infirmary, he underwent an emergency
ileostomy to bypass the blockage.
Its been like
a whirlwind, said Colin who will need to
undergo chemotherapy until mid-August. To
have something creep up on you like that when
you have absolutely no control over it really
makes you want to fight back. Thats why
I had no difficulty in agreeing to take part in
the trial.
Ive met some
amazing people since January and my treatment
on the NHS has been fantastic. The way I see it
is that Im being given the best possible
chance so in that sense I feel very fortunate.
Dr Joanna Reynolds, Cancer
Research UKs director of centres, said:
The Experimental Cancer Medicine Centres
Network supports research into some of the most
novel and exciting new anti-cancer therapies,
often providing the first insights into their
effect on cancer patients. By doing a clinical
trial like this we will find out more about the
potential benefits of taking large amounts of
curcumin, as well as any possible side effects
this could have for cancer patients.
For more information about
the trial, please visit www.cancerhelp.org.uk
or call the Cancer Research UK cancer information
nurses on 0808 800 4040.
About turmeric
Turmeric is part of the
ginger family and native to south Asia. It is
commonly used as the orange/yellow powder is a
spice for curries. Curcumin has an earthy, peppery
flavour and has been used for medicinal purposes
for centuries. Its potential use in Alzheimers,
arthritis and other disorders is also being investigated
around the world.
Top
|